Nuvalent Inc Quick Ratio (NUVL) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nuvalent Inc   (NASDAQ: NUVL)

Nuvalent Inc 's Quick Ratio

NUVL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Nuvalent Inc 's Cash & cash equivalent, this led to improvement in Nuvalent Inc 's Quick Ratio to 15.88, above Nuvalent Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Quick Ratio than Nuvalent Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 103 to 199.

Explain Quick Ratio?
How much Cash & cash equivalents NUVL´s has?
What are NUVL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NUVL Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 8.02 % 481.56 % 74.35 % 96.76 % 124.47 %
Y / Y Cash & cash equivalent Change 19.96 % 22.68 % -19.28 % 52.83 % 55.13 %
Quick Ratio MRQ 15.88 15.05 10.58 13.38 14.3
NUVL's Total Ranking # 199 # 103 # 268 # 188 # 150
Seq. Current Liabilities Change -11.1 % 2.27 % 18.64 % 0.15 % 378.62 %
Seq. Cash & cash equivalent Change -6.16 % 45.47 % -6.21 % -6.3 % -4.03 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 83
Overall Market # 199


Quick Ratio Statistics
High Average Low
44.2 12.87 0
(Sep 30 2021)   (Mar 31 2014)




Financial Statements
Nuvalent Inc 's Current Liabilities $ 81 Millions Visit NUVL's Balance sheet
Nuvalent Inc 's Cash & cash equivalent $ 1,287 Millions Visit NUVL's Balance sheet
Source of NUVL's Sales Visit NUVL's Sales by Geography


Cumulative Nuvalent Inc 's Quick Ratio

NUVL's Quick Ratio for the trailling 12 Months

NUVL Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 86.92 % 138.75 % 64.98 % 63.71 % 56.35 %
Y / Y Cash & cash equivalent TTM Growth 14.69 % 20.83 % 27.86 % 75.81 % 78.08 %
Quick Ratio TTM 13.69 13.29 16.24 20.12 22.32
Total Ranking TTM # 2358 # 2512 # 2551 # 2306 # 1689
Seq. Current Liabilities TTM Growth 1.82 % 29.6 % 17.52 % 20.53 % 30.06 %
Seq. Cash & cash equivalent TTM Growth 4.88 % 6.13 % -5.16 % 8.65 % 10.49 %

Quick ratio ranking by company, industry and sector >> Back to NUVL Financial Strength Comparisons >> Go to Compare NUVL Quick Ratio to its Competitors

On the trailing twelve months basis NUVL Cash & cash equivalent increased by 19.96 % in Q1 2026 year on year, faster than Current Liabilities, this led to increase in in Nuvalent Inc 's Quick Ratio to 13.69, above NUVL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 376 other companies have achieved higher Quick Ratio than Nuvalent Inc . While Quick Ratio overall ranking has improved so far to 2358, from total ranking during the twelve months ending fourth quarter 2025 at 2512.

Explain Quick Ratio?
How much Cash & cash equivalents NUVL´s has?
What are NUVL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 377
Healthcare Sector # 752
Within the Market # 2358


trailing twelve months Quick Ratio Statistics
High Average Low
33.88 11.4 0
(Mar 31 2022)   (Mar 31 2014)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Disc Medicine Inc   39.29 $ 730.158  Millions$ 18.586  Millions
Incannex Healthcare Inc  38.64 $ 74.450  Millions$ 1.927  Millions
Xbiotech Inc   38.50 $ 115.459  Millions$ 2.999  Millions
Contineum Therapeutics Inc   37.00 $ 246.328  Millions$ 6.657  Millions
Canton Strategic Holdings Inc   36.39 $ 41.532  Millions$ 1.141  Millions
Lb Pharmaceuticals Inc  35.93 $ 365.636  Millions$ 10.176  Millions
Pasithea Therapeutics Corp   33.84 $ 50.400  Millions$ 1.490  Millions
Fulcrum Therapeutics Inc   33.79 $ 333.316  Millions$ 9.864  Millions
Curanex Pharmaceuticals Inc  31.22 $ 4.019  Millions$ 0.129  Millions
Mbx Biosciences Inc   30.20 $ 439.977  Millions$ 14.567  Millions
Palvella Therapeutics Inc   28.73 $ 261.853  Millions$ 9.115  Millions
Xenon Pharmaceuticals Inc   27.50 $ 1,094.747  Millions$ 39.815  Millions
Climb Bio Inc   26.91 $ 109.564  Millions$ 4.071  Millions
Rapport Therapeutics Inc   26.64 $ 476.782  Millions$ 17.897  Millions
Tango Therapeutics Inc   26.51 $ 379.839  Millions$ 14.330  Millions
Structure Therapeutics Inc   25.59 $ 1,458.504  Millions$ 56.984  Millions
Trevi Therapeutics Inc   25.27 $ 171.783  Millions$ 6.797  Millions
Kezar Life Sciences Inc   23.98 $ 66.229  Millions$ 2.762  Millions
Arca Biopharma Inc  23.38 $ 388.829  Millions$ 16.633  Millions
Damora Therapeutics Inc   22.38 $ 532.899  Millions$ 23.812  Millions
Edgewise Therapeutics inc   22.16 $ 499.562  Millions$ 22.543  Millions
Keros Therapeutics Inc   21.90 $ 281.497  Millions$ 12.853  Millions
Design Therapeutics Inc   21.87 $ 222.823  Millions$ 10.190  Millions
Maplight Therapeutics Inc   21.71 $ 310.113  Millions$ 14.283  Millions
Upstream Bio Inc   21.55 $ 294.579  Millions$ 13.669  Millions
Monopar Therapeutics Inc   21.38 $ 52.544  Millions$ 2.458  Millions
Shattuck Labs Inc   21.28 $ 90.419  Millions$ 4.249  Millions
Immunome Inc   21.26 $ 582.693  Millions$ 27.412  Millions
Equillium Inc   21.12 $ 61.322  Millions$ 2.904  Millions
Generate Biomedicines Inc   20.78 $ 516.641  Millions$ 24.861  Millions

Date modified: 2026-10-05T11:03:40+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.